Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

As shown in Figure S4A, both normal and tumor PDOs, regardless of patient age, expressed comparable levels of VDR RNA encoding the vitamin D receptor.

Source: Calcitriol modulates drug resistance of normal and tumor PDOs. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Paired normal and tumor organoids from 5 EO-CRC and 6 LO-CRC patients were seeded in 12-well culture dishes and 48 h later were treated with calcitriol (100 nM) or vehicle (ethanol) for 96 h.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Calcitriol Modulates Age-dependent Drug Response in Paired Patient-derived Normal and Tumor Colorectal Organoids

Study design awaiting verification · International Journal of Biological Sciences · 2026

Original publication title

Calcitriol Modulates Age-dependent Drug Response in Paired Patient-derived Normal and Tumor Colorectal Organoids

Asunción Fernández-Barral; Antonio Barbáchano; Silvia Rodríguez-Marrero; Luis del Peso; Alfonso Herreros-Cabello; Estrella Arroyo-Gascón; Nuria Rodríguez-Salas; Isabel Prieto; Aurora Burgos; Miguel León-Arellano; Damián García-Olmo; Tomás Olleros; José Manuel González-Sancho; María Jesús Larriba; Alberto Muñoz

© The author(s)

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The incidence of early-onset colorectal cancer (EO-CRC, <50 years) is rising worldwide, highlighting the need to better understand the underlying causes of this age-related divergence. We used paired patient-derived normal and tumor colorectal organoids to investigate the therapeutic window of chemotherapeutic agents and its modulation by calcitriol (the most active vitamin D metabolite). Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil (5-FU) and oxaliplatin. Normal organoids were more resistant than paired tumor counterparts to 5-FU and oxaliplatin in both EO-CRC and late-onset CRC (LO-CRC, >50 years), indicating selective tumor cytotoxicity.

In contrast, the therapeutic window for SN38 was preserved in LO-CRC but not in EO-CRC organoids, revealing age-dependent differences in drug sensitivity. Moreover, calcitriol reduced the cytotoxicity of 5-FU and SN38 in normal organoids regardless of patient age, while in tumor organoids this protective effect was restricted to EO-CRC. As a consequence, calcitriol treatment selectively expanded the therapeutic window for 5-FU and SN38 in LO-CRC organoids. Mechanistically, these effects correlated with calcitriol-induced antiproliferative action and transcriptional regulation of drug metabolism-related pathways.

Overall, our findings identify age-dependent differences in chemotherapy response and support the importance of maintaining adequate vitamin D status to reduce chemotherapy-associated toxicity.

Authors’ abstract

The incidence of early-onset colorectal cancer (EO-CRC, <50 years) is rising worldwide, highlighting the need to better understand the underlying causes of this age-related divergence. We used paired patient-derived normal and tumor colorectal organoids to investigate the therapeutic window of chemotherapeutic agents and its modulation by calcitriol (the most active vitamin D metabolite). Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil (5-FU) and oxaliplatin. Normal organoids were more resistant than paired tumor counterparts to 5-FU and oxaliplatin in both EO-CRC and late-onset CRC (LO-CRC, >50 years), indicating selective tumor cytotoxicity.

In contrast, the therapeutic window for SN38 was preserved in LO-CRC but not in EO-CRC organoids, revealing age-dependent differences in drug sensitivity. Moreover, calcitriol reduced the cytotoxicity of 5-FU and SN38 in normal organoids regardless of patient age, while in tumor organoids this protective effect was restricted to EO-CRC. As a consequence, calcitriol treatment selectively expanded the therapeutic window for 5-FU and SN38 in LO-CRC organoids. Mechanistically, these effects correlated with calcitriol-induced antiproliferative action and transcriptional regulation of drug metabolism-related pathways.

Overall, our findings identify age-dependent differences in chemotherapy response and support the importance of maintaining adequate vitamin D status to reduce chemotherapy-associated toxicity.

Publication and source details

Original title: Calcitriol Modulates Age-dependent Drug Response in Paired Patient-derived Normal and Tumor Colorectal Organoids

Asunción Fernández-Barral; Antonio Barbáchano; Silvia Rodríguez-Marrero; Luis del Peso; Alfonso Herreros-Cabello; Estrella Arroyo-Gascón; Nuria Rodríguez-Salas; Isabel Prieto; Aurora Burgos; Miguel León-Arellano; Damián García-Olmo; Tomás Olleros; José Manuel González-Sancho; María Jesús Larriba; Alberto Muñoz

International Journal of Biological Sciences · 2026

✉ Corresponding author: Asunción Fernández-Barral or María Jesús Larriba, Instituto de Investigaciones Biomédicas Sols-Morreale, Arturo Duperier, 4, 28029 Madrid, Spain; E-mail: afbarral@iib.uam.es / mjlarriba@iib.uam.es.

# Indicates equal contribution.

† Present address: National Centre for Biotechnology (CNB-CSIC), 28049 Madrid, Spain.

Competing Interests: Tomás Olleros is president of Grupo Farmasierra. All other authors have declared no conflicts of interest.

© The author(s)2026https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See https://ivyspring.com/terms for full terms and conditions.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-08T18:35:28+00:00

DOI: 10.7150/ijbs.131639 · PMC13540450